BCL2 and B-cell chronic lymphocytic leukemia: Pirtobrutinib (LOXO-305, Jaypirca, Eli Lilly, Indianapolis, IN, USA) received FDA approval in December 2023 to treat patients with CLL who had previously received both a cBTKis and a BCL-2 inhibitor [34].